Here are relevant reports on : biologics-market
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Biopharmaceutical Process Analytical Technology Market Size by Technology (LC, GC, MS, qPCR, NGS, NMR, Raman, IR Spectroscopy), Product (Analyzer, Sensor, Software), Application (Vaccine, Biologics, CGT), and End User - Global Forecast to 2029
The global biopharmaceutical process analytical technology market, valued at US$1.0 billion in 2023, stood at US$1.2 billion in 2024 and is projected to advance at a resilient CAGR of 16.0% from 2024 to 2029, culminating in a forecasted valuation of US$2.6 billion by the end of the period. The market is witnessing a surge in growth propelled by rising investments, both direct and indirect, in analytical instruments, coupled with strategic partnerships aimed at advancing drug discovery.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Spinal Implants Market by Product (Devices (Thoracic, Cervical, Interbody Fusion, Spinal Non-Fusion), Biologics, Stimulators), Application (VCF, Spinal Decompression, Fusion, Non-Fusion), Surgery (Open, MIS), Region & Customer Unmet Need Forecast to 2028
The global spinal implants market, valued at US$10.7 billion in 2022, stood at US$11.2 billion in 2023 and is projected to advance at a resilient CAGR of 5.0% from 2023 to 2028, culminating in a forecasted valuation of US$14.3 billion by the end of the period. Increasing incidence of spinal disorder and research on spinal implants by key companies have resulted in the development are the major factors driving market growth.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029
The global biologics safety testing market, valued at US$3.9 billion in 2023, stood at US$4.2 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$7.2 billion by the end of the period. Growth of the market can be attributed to factors such as the rising need for novel biotherapeutics and increasing focus on advancement of biopharmaceutical industry.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
- Published: May 2019
- Price: $ 4950
- TOC Available:
-
Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Global Forecast to 2021
The global top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between 2016 and 2021. Growth in the biopharmaceutical industry, increase in R&D spending, rising demand for vaccine production, and technological advancements form important growth drivers for this market. On the other hand, stringent regulatory policies and high cost of instruments are restraining market growth for bioprocess technologies.
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030
The global drug discovery services market, valued at US$14.89B in 2024, is forecasted to grow at a 10.7% CAGR, reaching US$16.36B by 2025 and US$27.23B by 2030. Growing awareness about personalized medicines and targeted therapies, a vast patient population, and emerging middle-class population are enhancing market penetration in the Asia Pacific region.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
Facial Implant Market by Product (Chin, Nasal, Malar, Jaw, Injectable), Material (Metal, Biologics, Polymers, Ceramics, Silicon), Shape (Anatomical, Oval, Round), Procedure (Rhinoplasty, Rhytidectomy, Chin Augmentation, Eyelid, Cheekbone, Forehead), End User (Hospitals, ASCs) - Global Forecasts to 2027
The global facial implants market is projected to reach USD 4.2 billion by 2027 from USD 2.7 Billion in 2022, at a CAGR of 8% during the forecast period. The technological advancements majorly drive the growth in the facial implants market, the growing adoption of minimally invasive aesthetic procedures, the rising popularity of cosmetic procedures, and an increasing number of trauma cases and road accidents.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Human Insulin Market By Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2020
The global human insulin market size is projected to grow at a CAGR of 8.1%. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of this market.
- Published: December 2015
- Price: $ 4950
- TOC Available:
-
Burn Care Market by Product (Advanced (Collagen, Film, Hydrogel, Foam, Alginate Dressings), Therapy Devices (Debridement, NPWT), Biologics, Traditional), Burn Degree (First, Second, Third-degree Burns), End User (Hospitals, ASCs) - Global Forecast to 2030
The global burn care market, valued at US$2.46 billion in 2024, stood at US$2.55 billion in 2025 and is projected to advance at a resilient CAGR of 5.6% from 2025 to 2030, culminating in a forecasted valuation of US$3.35 billion by the end of the period. This market is experiencing consistent growth due to several key factors.
- Published: May 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
